Advanced our Path to a Cure initiative, funding more than 50 research programs with leading and emerging biotech companies to apply the world’s most innovative science to CF.
Began conducting early-phase clinical trials for genetic-based therapies, including promising messenger RNA therapies, which have the potential to help anyone with CF. Genetic therapy trials represent the first step on a journey that will take time and persistence — and we are ready to go the distance.
Celebrated the Therapeutics Development Network’s (TDN) 25th anniversary. As the largest CF clinical trial network in the world, the TDN has conducted hundreds of clinical studies to speed the delivery of new and better treatments.
Brought modulators to younger children and simultaneously expanded our research portfolio of potential new modulators to offer greater therapeutic choice in the future.
Funded more than 130 CF care centers nationwide, enabling multidisciplinary care teams to deliver the gold standard in CF care. As part of our commitment to supporting care, we collaborated internationally to improve and expand access to CF care and treatments in dozens of countries.
Broadened our research efforts to further address the serious health complications associated with CF, such as gastrointestinal issues, advanced lung disease, mental health, and difficult-to-treat infections.
Advocated with leading policymakers in Congress and federal agencies to encourage the development of novel antibiotics and other needed medications — and to promote access to them.
Continued to address health inequities in CF, including delays in diagnosis and other barriers to care.
Raised more than $140 million toward a $200 million goal, as part of our Milestones III: Driven by Dream fundraising campaign — so vital to sustaining our research efforts.
Offered people with CF emotional support, new connections, and resources to meet their changing needs, desires, and dreams.